DiaMedica Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate
DiaMedica Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate
DiaMedica Therapeutics 2024年第一季度GAAP每股收益美元（0.14美元）超过预期（0.16美元）
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 30 percent increase over losses of $(0.20) per share from the same period last year.
DiaMedica Therapeutics（纳斯达克股票代码：DMAC）公布的季度亏损为每股0.14美元，比分析师普遍预期的0.16美元（0.16美元）高出12.5％。这比去年同期每股亏损0.20美元（0.20）增长了30％。